Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update
FDA PDUFA review goal date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT)Assuming ...
Nasdaq2d
Milestone Pharmaceuticals Reports FDA PDUFA Review Date for CARDAMYST™ Nasal Spray Targeting PSVT, Plans for Mid-2025 Launch
Milestone Pharmaceuticals Inc. announced that the FDA has set a PDUFA review goal date of March 27, 2025, for its nasal spray CARDAMYST™ (etripamil), aimed at treating Paroxysmal ...
Morningstar3d
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update
The study will use the patient self-administration 70-mg repeat-dose regimen, of etripamil nasal spray, outside of the medically supervised setting, similar to that used in the PSVT development ...
Business Insider25d
Milestone receives notice of allawance from USPTO on etripamil nasal spray
on a new Method of Use patent for etripamil nasal spray, with proposed trade name CARDAMYST, its lead investigational product for the management of paroxysmal supraventricular tachycardia ...
manilatimes3d
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update
The study will use the patient self-administration 70-mg repeat-dose regimen, of etripamil nasal spray, outside of the medically supervised setting, similar to that used in the PSVT development ...
Yahoo Finance25d
Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil
Etripamil is Milestone's lead investigational product. It is a novel calcium channel blocker nasal spray under clinical development for frequent and often highly symptomatic episodes of PSVT and ...
Stockhouse2d
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update
Etripamil is Milestone's lead investigational product. It is a novel calcium channel blocker nasal spray under clinical development for frequent and often highly symptomatic episodes of PSVT and ...
Pulmonology Advisor10d
FDA Drug Approval Decisions Expected in March 2025
The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics License Application (BLA ...
Morningstar25d
Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil
Morningstar brands and products Company Portfolio ...
manilatimes25d
Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil
The CARDAMYST brand name is conditionally approved by the FDA. Etripamil is Milestone's lead investigational product. It is a novel calcium channel blocker nasal spray under clinical development for ...